Solventum Corporation (SOLV) — Analysis Summary
Solventum Corporation (SOLV) has a market cap of $13.41B with year-over-year revenue growth of +0.9%. Net margin stands at 18.7%. The stock trades at a P/E ratio of 9.4.
Key Takeaways
- Revenue changed +0.9% year-over-year
- Net margin of 18.7%
- P/E ratio of 9.4
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, SOLV posted revenue growth of +0.9% and trades at a P/E of 9.4.
Solventum Corporation (SOLV)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
The latest filing shows negative free cash flow.
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
20,000
Headquarters
EAGAN, MN
Exchange
XNYS
At least 3 years of annual financial data required to assess competitive moat.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.